Literature DB >> 6092812

Naltrexone modulates body and brain development in rats: a role for endogenous opioid systems in growth.

I S Zagon, P J McLaughlin.   

Abstract

Preweaning rats receiving daily injections of 20, 50, or 100 mg/kg naltrexone, a potent opiate antagonist, had body and brain weights that were increased 16-22% and 6-13%, respectively, from control levels on day 21 (weaning). All of these dosages of naltrexone blocked the opiate receptor for 24 hr/day as measured in opiate challenge experiments. Dosages of 0.1, 1, and 10 mg/kg naltrexone, which blocked the opiate receptor for less than 12 hr/day, inhibited growth. Repetitive administration of low dosages (3 mg/kg naltrexone, 3 times daily), which blocked the receptor 24 hr/day, increased body and brain development by 31% and 10%, respectively, whereas a cumulative dosage of 9 mg/kg naltrexone given once daily retarded growth. These results show that developmental events are dictated by the duration of opiate receptor blockade and provide compelling evidence that endogenous opioid systems play a crucial role in growth.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092812     DOI: 10.1016/0024-3205(84)90563-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

Review 1.  Developmental consequences of fetal exposure to drugs: what we know and what we still must learn.

Authors:  Emily J Ross; Devon L Graham; Kelli M Money; Gregg D Stanwood
Journal:  Neuropsychopharmacology       Date:  2014-06-18       Impact factor: 7.853

2.  Localization of enkephalin immunoreactivity in diverse tissues and cells of the developing and adult rat.

Authors:  I S Zagon; R E Rhodes; P J McLaughlin
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

3.  Knockout of the mu opioid receptor enhances the survival of adult-generated hippocampal granule cell neurons.

Authors:  G C Harburg; F S Hall; A V Harrist; I Sora; G R Uhl; A J Eisch
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

4.  Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects.

Authors:  Elisha M Wachman; Kelley Saia; Melissa Miller; Eduardo Valle; Hira Shrestha; Ginny Carter; Martha Werler; Hendree Jones
Journal:  Clin Ther       Date:  2019-07-27       Impact factor: 3.393

5.  Brain opioids and autism: an updated analysis of possible linkages.

Authors:  T L Sahley; J Panksepp
Journal:  J Autism Dev Disord       Date:  1987-06

Review 6.  Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models.

Authors:  D Rice; S Barone
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

7.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

8.  Maternally administered sustained-release naltrexone in rats affects offspring neurochemistry and behaviour in adulthood.

Authors:  Waleed O Farid; Andrew J Lawrence; Elena V Krstew; Robert J Tait; Gary K Hulse; Sarah A Dunlop
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

9.  Larger Numbers of Glial and Neuronal Cells in the Periaqueductal Gray Matter of μ-Opioid Receptor Knockout Mice.

Authors:  Kazumasu Sasaki; Frank Scott Hall; George R Uhl; Ichiro Sora
Journal:  Front Psychiatry       Date:  2018-09-19       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.